Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors
Conclusions Afatinib/gemcitabine and afatinib/docetaxel demonstrated manageable safety profiles, with evidence of clinical efficacy at the MTDs. For afatinib/docetaxel, a dose level of afatinib 30 mg/docetaxel 75 mg/m2 produced higher response rates.Trial registration: NCT01251653 (ClinicalTrials.gov).
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Chemotherapy | Docetaxel | Drugs & Pharmacology | Investigational New Drugs | Study | Taxotere | Thrombocytopenia | Toxicology